Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Advanced Renal Cell Carcinoma Treatment Market to Grow by $3.1 Billion During 2026-2030: Global Industry Assessment Featuring Pfizer, Merck & Co., Bristol-Myers Squibb, AstraZeneca, Novartis and More

globenewswire.com
MRK Merck & Co. is developing innovative therapies like HIF-2 alpha inhibitors and received FDA approval for WELIREG, a novel treatment for advanced RCC, indicating positive progress and market impact. EXEL Exelixis Inc. is partnering with Arcus Biosciences to develop cancer therapies, including for RCC, through clinical trials, aiming to accelerate treatment innovation and benefit the market. PFE Pfizer Inc. is listed as a prominent player in the advanced RCC treatment market, suggesting its involvement and potential contribution to market growth. BMY Bristol-Myers Squibb is mentioned as a key company in the advanced RCC treatment market, indicating its presence and potential role in market developments. AZN AstraZeneca is listed as a prominent player in the advanced RCC treatment market, suggesting its involvement and potential contribution to market growth. NVS Novartis is mentioned as a prominent player in the advanced RCC treatment market, indicating its presence and potential role in market developments.

Advanced Renal Cell Carcinoma Treatment Market to Grow by $3.1 Billion During 2026-2030: Global Industry Assessment Featuring Pfizer, Merck & Co., Bristol-Myers Squibb, AstraZeneca, Novartis and More Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Advanced Renal Cell Carcinoma Treatment Market Report 2026" has been added to ResearchAndMarkets.com's offering.

The report outlines opportunities for growth, with insights into emerging markets and segmentation to inform strategic endeavors in the advanced RCC treatment landscape.

The advanced renal cell carcinoma (RCC) treatment market has demonstrated significant growth, with projections indicating an increase from $8.73 billion in 2025 to $9.4 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.7%. This expansion results from limited treatment options for advanced RCC, reliance on conventional chemotherapy, rising prevalence of RCC, and the expansion of hospital oncology services and clinical research initiatives.

Looking ahead, the market is expected to reach $12.52 billion by 2030, with a CAGR of 7.4%. This growth is attributed to novel biologics, targeted inhibitors, investment in immunotherapy research, and the adoption of personalized medicine and minimally invasive procedures. Key trends include the adoption of targeted therapies, immune checkpoint inhibitors, combination therapy approaches, and the development of cancer vaccines.

The prevalence of genetic conditions is anticipated to drive the growth of the advanced RCC treatment market. With advancements in diagnostics, increased awareness, and environmental influences, genetic conditions are becoming more prevalent. Advanced RCC treatments target specific molecular pathways, offering personalized therapies for tumor development. For instance, Gene People estimated that 1 in 25 children in the UK are affected by genetic conditions, contributing to the market's growth.

Major companies like Merck & Co. Inc. are developing innovative therapies such as hypoxia-inducible factor-2 alpha (HIF-2?) inhibitors. In December 2023, Merck received FDA approval for WELIREG (belzutifan), an oral HIF-2 inhibitor, providing a novel treatment for patients with limited options, enhancing outcomes and management of advanced RCC.

In December 2023, Exelixis Inc. partnered with Arcus Biosciences Inc. to develop cancer therapies, focusing on RCC and other tumors through the STELLAR-009 clinical trial. This collaboration aims to accelerate treatment innovation, benefitting the advanced RCC treatment arena.

Prominent players in the market include Pfizer Inc, Bristol-Myers Squibb, AstraZeneca, Novartis, Exelixis, and others, with North America being the largest region in 2025. The market is segmented across Asia-Pacific, Western Europe, North America, and other regions, with countries like the USA, UK, China, and Germany leading the charge.

Reasons to Purchase:

Report Scope

Markets Covered:

Subsegments:

Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

Regions: Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Time Series: Five years historic and ten years forecast

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita

Delivery Format: Available in Word, PDF, Interactive Report, plus Excel Dashboard

Key Attributes

The companies featured in this Advanced Renal Cell Carcinoma Treatment market report include:

For more information about this report visit https://www.researchandmarkets.com/r/4ngp0p

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment